Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical on track to begin Alzheimer’s disease trial

The company has received approval for the trial in the UK.
Actinogen Medical on track to begin Alzheimer’s disease trial
Xanamem is designed to block the excess production of cortisol

Actinogen Medical (ASX:ACW) has received the approval in the UK to conduct its Phase II clinical trial of Xanamem™ for mild Alzheimer’s disease.

The trial was approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) following the regulatory approval received from the FDA in the U.S. in January 2017.

These approvals provide a strong endorsement of Actinogen’s progress towards the treatment of Alzheimer’s and underscores the quality of Actinogen's existing research data on Xanamem.

Xanamem has been specifically designed to block the excess production of cortisol, the stress hormone, in the areas of the brain most affected by Alzheimer’s disease.

Raised cortisol has been strongly associated with Alzheimer’s disease and lowering cortisol in the brain is an important new target for treating Alzheimer’s disease.

Actinogen will conduct the Phase II double-blind, 12-week study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease.

The company will enrol 174 patients at research sites across the UK, U.S. and Australia as part of the trial.

Inhibiting the production of cortisol in the brain with Xanamem could have a major impact on the wellbeing of people living with dementia as well as those at high risk of developing this condition.

Actinogen expects to shortly receive approval from the Australian Therapeutic Goods Administration
(TGA) to conduct the trial in Australia.

This will be the last major regulatory approval required before the company can begin actively recruiting.

Actinogen’s share price has increased by more than 53% during the past three months, last trading at $0.06.

The company is well funded with a cash balance of circa $5.8 million as at 31 December 2016.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

test tubes
January 23 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
Summit
January 26 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said
girl sneezing
Tue
The Phase II study of its PQ Grass immunotherapy, an aluminium-free, ultra-short course hay fever treatment, is designed to evaluate dose response and safety

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use